Difference between revisions of "Fotemustine (Muphoran)"
Jump to navigation
Jump to search
m |
m |
||
Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
− | *[[ | + | *[[Diffuse large B-cell lymphoma]] |
+ | *[[Hodgkin lymphoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
− | *[[Uveal melanoma]] | + | **[[CNS melanoma]] |
+ | **[[Uveal melanoma]] | ||
==Also known as== | ==Also known as== | ||
Line 14: | Line 16: | ||
[[Category:Nitrosoureas]] | [[Category:Nitrosoureas]] | ||
+ | [[Category:Diffuse large B-cell lymphoma medications]] | ||
+ | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Uveal melanoma medications]] | [[Category:Uveal melanoma medications]] | ||
[[Category:EMA approved drugs]] | [[Category:EMA approved drugs]] |
Revision as of 01:41, 14 May 2022
Mechanism of action
From the NCI Drug Dictionary: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.
Diseases for which it is used
Also known as
- Brand names: Muphoran, Mustophoran